Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Rilmakalim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 known ✓ | O60706 | 15/20 | 0.64 |
| ▸ | KCNJ11 known ✓ | Q14654 | 2/20 | 0.64 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.38 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.64 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rilmakalim SCHEMBL1231447 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL4410403 | 1.00 | ABCC9 (0.64) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL221620 | 0.99 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9585284 | 0.99 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL29900877 | 0.99 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9293211 | 0.99 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9293204 | 0.99 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| Rilmakalim SCHEMBL9295497 | 0.95 | ABCC9 (0.59) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9294498 | 0.91 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 | |
| SCHEMBL9293335 | 0.91 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663239-A4 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS SINAI MEDICAL CENTER (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1663239-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | CEDARS-SINAI MEDICAL CENTER | 2005-04-28 | — | — | US | disclosed |
| WO-2005025511-A2 | POTASSIUM CHANNEL MEDIATED DELIVERY OF AGENTS THROUGH THE BLOOD-BRAIN BARRIER | CEDARS-SINAI MEDICAL CENTER (US) | 2005-03-24 | — | — | WO | disclosed |
| US-5310753-A | Ethanol adducts of 6-sulfonyl-substituted 3-hydroxy-chromans and their use as inhalants in diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885KCNJ11 24/4885MEN1 1234/4885 |
| US-20050089473-A1 | Potassium channel mediated delivery of agents through the blood-brain barrier | KCNN2, KCNN1, KCNN3 | ABCC9 115/4885KCNJ11 18/4885MEN1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.